Literature DB >> 28379451

Detection of genetic loci associated with plasma fetuin-A: a meta-analysis of genome-wide association studies from the CHARGE Consortium.

Majken K Jensen1, Richard A Jensen2, Kenneth J Mukamal3, Xiuqing Guo4, Jie Yao4, Qi Sun1, Marilyn Cornelis5, Yongmei Liu6, Ming-Huei Chen7,8, Jorge R Kizer9, Luc Djoussé10, David S Siscovick11, Bruce M Psaty2,12, Joseph M Zmuda13, Jerome I Rotter4, Melissa Garcia14, Tamara Harris15, Ida Chen4, Mark O Goodarzi16, Michael A Nalls14, Margaux Keller14, Alice M Arnold17, Anne B Newman13, Ron C Hoogeveen18, Kathryn M Rexrode19, Eric B Rimm1, Frank B Hu1, Vasan S Ramachandran20,8, Ronit Katz4, James S Pankow21, Joachim H Ix22.   

Abstract

Plasma fetuin-A is associated with type 2 diabetes, and AHSG, the gene encoding fetuin-A, has been identified as a susceptibility locus for diabetes and metabolic syndrome. Thus far, unbiased investigations of the genetic determinants of plasma fetuin-A concentrations have not been conducted. We searched for single nucleotide polymorphisms (SNPs) related to fetuin-A concentrations by a genome-wide association study in six population-based studies. We examined the association of fetuin-A levels with ∼ 2.5 million genotyped and imputed SNPs in 9,055 participants of European descent and 2,119 African Americans. In both ethnicities, the strongest associations were centered in a region with a high degree of LD near the AHSG locus. Among 136 genome-wide significant (P < 0.05 × 10-8) SNPs near the AHSG locus, the top SNP was rs4917 (P =1.27 × 10-303), a known coding SNP in exon 6 that is associated with a 0.06 g/l (∼13%) lower fetuin-A level. This variant alone explained 14% of the variation in fetuin-A levels. Analyses conditioned on rs4917 indicated that the strong association with the AHSG locus stems from additional independent associations of multiple variants among European Americans. In conclusion, levels of fetuin-A in plasma are strongly associated with SNPs in its encoding gene, AHSG, but not elsewhere in the genome. Given the strength of the associations observed for multiple independent SNPs, the AHSG gene is an example of a candidate locus suitable for additional investigations including fine mapping to elucidate the biological basis of the findings and further functional experiments to clarify AHSG as a potential therapeutic target. Published by Oxford University Press 2017. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28379451      PMCID: PMC6075215          DOI: 10.1093/hmg/ddx091

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   5.121


  39 in total

1.  Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.

Authors:  A H Kissebah; G E Sonnenberg; J Myklebust; M Goldstein; K Broman; R G James; J A Marks; G R Krakower; H J Jacob; J Weber; L Martin; J Blangero; A G Comuzzie
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Association of fetuin-A level and diabetes risk.

Authors:  Norbert Stefan; Hans-Ulrich Häring; Matthias B Schulze
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

3.  Fetuin-null mice are protected against obesity and insulin resistance associated with aging.

Authors:  Suresh T Mathews; Sanjay Rakhade; Xiaohua Zhou; Graham C Parker; Donald V Coscina; George Grunberger
Journal:  Biochem Biophys Res Commun       Date:  2006-09-25       Impact factor: 3.575

4.  AHSG gene variation is not associated with regional body fat distribution--a magnetic resonance study.

Authors:  K Müssig; H Staiger; F Machicao; J Machann; A M Hennige; F Schick; C D Claussen; A Fritsche; H-U Häring; N Stefan
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-04-08       Impact factor: 2.949

5.  Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A.

Authors:  Bernd Denecke; Steffen Gräber; Cora Schäfer; Alexander Heiss; Michael Wöltje; Willi Jahnen-Dechent
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

6.  A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity.

Authors:  Mari Inoue; Hiroshi Takata; Yukio Ikeda; Tadashi Suehiro; Shojiro Inada; Fumiaki Osaki; Kaoru Arii; Yoshitaka Kumon; Kozo Hashimoto
Journal:  Diabetes Res Clin Pract       Date:  2007-09-24       Impact factor: 5.602

7.  AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects.

Authors:  Gitte Andersen; Kristoffer Sølvsten Burgdorf; Thomas Sparsø; Knut Borch-Johnsen; Torben Jørgensen; Torben Hansen; Oluf Pedersen
Journal:  Diabetes       Date:  2008-03-03       Impact factor: 9.461

8.  Fetuin-A and risk of coronary heart disease: A Mendelian randomization analysis and a pooled analysis of AHSG genetic variants in 7 prospective studies.

Authors:  Lars E Laugsand; Joachim H Ix; Traci M Bartz; Luc Djousse; Jorge R Kizer; Russell P Tracy; Abbas Dehghan; Kathryn Rexrode; Oscar L Lopez; Eric B Rimm; David S Siscovick; Christopher J O'Donnell; Anne Newman; Kenneth J Mukamal; Majken K Jensen
Journal:  Atherosclerosis       Date:  2015-09-05       Impact factor: 5.162

9.  Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level.

Authors:  P R Srinivas; A S Wagner; L V Reddy; D D Deutsch; M A Leon; A S Goustin; G Grunberger
Journal:  Mol Endocrinol       Date:  1993-11

10.  Plasma fetuin-A levels and the risk of type 2 diabetes.

Authors:  Norbert Stefan; Andreas Fritsche; Cornelia Weikert; Heiner Boeing; Hans-Georg Joost; Hans-Ulrich Häring; Matthias B Schulze
Journal:  Diabetes       Date:  2008-07-15       Impact factor: 9.461

View more
  5 in total

Review 1.  Genetic variants of mineral metabolism in health and disease.

Authors:  Cassianne Robinson-Cohen
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-07       Impact factor: 2.894

2.  Circulating Fetuin-A and Risk of Type 2 Diabetes: A Mendelian Randomization Analysis.

Authors:  Janine Kröger; Karina Meidtner; Norbert Stefan; Marcela Guevara; Nicola D Kerrison; Eva Ardanaz; Dagfinn Aune; Heiner Boeing; Miren Dorronsoro; Courtney Dow; Guy Fagherazzi; Paul W Franks; Heinz Freisling; Marc J Gunter; José María Huerta; Rudolf Kaaks; Timothy J Key; Kay Tee Khaw; Vittorio Krogh; Tilman Kühn; Francesca Romana Mancini; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Elena Salamanca-Fernández; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Konstantinos K Tsilidis; Rosario Tumino; Yvonne T van der Schouw; Nita G Forouhi; Stephen J Sharp; Claudia Langenberg; Elio Riboli; Matthias B Schulze; Nicholas J Wareham
Journal:  Diabetes       Date:  2018-03-09       Impact factor: 9.461

Review 3.  Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet.

Authors:  Magnus Bäck; Tamas Aranyi; M Leonor Cancela; Miguel Carracedo; Natércia Conceição; Georges Leftheriotis; Vicky Macrae; Ludovic Martin; Yvonne Nitschke; Andreas Pasch; Daniela Quaglino; Frank Rutsch; Catherine Shanahan; Victor Sorribas; Flora Szeri; Pedro Valdivielso; Olivier Vanakker; Hervé Kempf
Journal:  Front Cardiovasc Med       Date:  2019-01-18

4.  Genetic Determinants of Serum Calcification Propensity and Cardiovascular Outcomes in the General Population.

Authors:  Amber de Haan; Fariba Ahmadizar; Peter J van der Most; Chris H L Thio; Zoha Kamali; Alireza Ani; Mohsen Ghanbari; Layal Chaker; Joyce van Meurs; M Kamran Ikram; Harry van Goor; Stephan J L Bakker; Pim van der Harst; Harold Snieder; Maryam Kavousi; Andreas Pasch; Mark Eijgelsheim; Martin H de Borst
Journal:  Front Cardiovasc Med       Date:  2022-01-14

Review 5.  Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.

Authors:  Ojus Sardana; Ravi Goyal; Onkar Bedi
Journal:  Inflammopharmacology       Date:  2021-06-29       Impact factor: 4.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.